natgillin/translations-raw huggingface dataset:
In another clinical study (D-Pan-H5N1-015), 39 subjects aged 18-60 years received a dose of AS03- adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/5/2005 fourteen months after they had received two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 administered on day 0 and day 21.
V drugi klinični študiji (D-Pan-H5N1-015) je 39 preiskovancev, starih od 18 do 60 let, dobilo cepivo z adjuvansom AS03 z vsebnostjo 3,75 µg HA, pridobljenega iz A/Indonesia/05/2005 štirinajst mesecev potem, ko so dobili dva odmerka cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz A/Vietnam/1194/2004 na dan 0 in 21.
In another clinical study (D-Pan-H5N1-038), 387 subjects aged 18-60 years received 1 dose of AS03- adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/5/2005 36 months after they had received two doses of A/Vietnam/1194/2004.
V klinični študiji (D-Pan-H5N1-038) je 387 preiskovancev, starih od 18 do 60 let, prejelo 1 odmerek cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA, pridobljenega iz A/Indonesia/05/2005 36 mesecev potem, ko so prejeli dva odmerka A/Vietnam/1194/2004.
In another clinical study, 39 subjects aged 18-60 years received a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/5/2005 fourteen months after they had received two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 administered on day 0 and day 21.
V drugi klinični študiji je 39 preiskovancev, starih od 18 do 60 let, dobilo cepivo z adjuvansom AS03 z vsebnostjo 3,75 µg HA iz A/Indonesia/05/2005 štirinajst mesecev potem, ko so dobili dva odmerka cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA iz A/Vietnam/1194/2004 na dan 0 in 21.
In another clinical trial, the efficacy and safety of Rasilez HCT were also assessed in 489 obese hypertensive patients who did not respond to hydrochlorothiazide 25 mg (baseline systolic/diastolic blood pressure 149.4/96.8 mmHg).
V drugem kliničnem preskušanju so učinkovitost in varnost zdravila Rasilez HCT ocenjevali tudi pri 489 debelih hipertenzivnih bolnikih, ki se niso ustrezno odzvali na zdravljenje s 25 mg hidroklorotiazida (s sistoličnim/diastoličnim krvnim tlakom ob izhodišču 149,4/96,8 mmHg).
In another ITP clinical trial, no accumulation in serum concentrations was observed after 6 weekly doses of romiplostim (3 μg/kg).
V drugem kliničnem preskušanju ITP po 6 tedenskih odmerkih romiplostima (3 µg/kg) niso opazili kopičenja koncentracije v serumu.
In another long-term 26-week controlled trial, the incidence of EPS was 14.8% for aripiprazole-treated patients and 15.1% for olanzapine- treated patients.
V drugem dolgoročnem 26-tedenskem nadzorovanem preskušanju je bila incidenca EPS pri bolnikih, zdravljenih z aripiprazolom, 14,8 % in pri bolnikih, zdravljenih z olanzapinom, 15,1 %.
In another long-term study, there was an increased incidence of bone fracture for subjects in the combined rosiglitazone group compared to active control [8.3% vs 5.3%, Risk ratio 1.57 (95% CI 1.26 - 1.97)].
V drugi dolgoročni študiji so ugotovili večjo incidenco zlomov kosti pri preiskovancih v kombinirani skupini z rosiglitazonom kot v skupini s primerjalno učinkovino [8,3 % v prim. s 5,3 %, razmerje tveganj 1,57 (95 % IZ 1,26-1,97)].
In another main study in 376 patients with lung cancer, treatment with Lonquex was superior to placebo (a dummy treatment) in reducing the time it took to recover from neutropenia as well as the occurrence and duration of severe neutropenia.
V drugi glavni študiji s 376 bolniki z rakom pljuč je bilo zdravilo Lonquex učinkovitejše od placeba (zdravila brez zdravilne učinkovine) pri skrajšanju časa, potrebnega za okrevanje po nevtropeniji, ter pri zmanjšanju pojavljanja in skrajšanju trajanja hude nevtropenije.
In another main study Stivarga was compared with placebo in 199 patients with GIST that had spread or was inoperable and who were also given best supportive care.
V drugi glavni študiji so zdravilo Stivarga primerjali s placebom pri 199 bolnikih z gastrointestinalnim stromalnim tumorjem, ki se je razširil ali ga ni mogoče kirurško odstraniti in ki so prejemali tudi najboljšo podporno oskrbo.
In another monotherapy study in mild to moderate Alzheimer’s disease a total of 470 patients (MMSE total scores at baseline of 11 - 23) were randomised.
V drugi študiji zdravljenja z monoterapijo pri blagi do zmerni Alzheimerjevi bolezni (skupna ocena pri KPSS ob vključitvi od 11 do 23 točk), je bilo zajetih in randomiziranih 470 bolnikov.
In another monotherapy study in mild to moderate Alzheimer’s disease a total of 470 patients (MMSE total scores at baseline of 11 − 23) were randomised.
V drugi študiji zdravljenja z monoterapijo pri blagi do zmerni Alzheimerjevi bolezni (skupna ocena pri KPSS ob vključitvi od 11 do 23 točk), je bilo zajetih in randomiziranih 470 bolnikov.
In another monotherapy study in mild to moderate Alzheimer’s disease a total of 470 patients (MMSE total scores at baseline of 11-23) were randomised.
Pri drugi študiji zdravljenja v monoterapiji pri blagi do zmerni Alzheimerjevi bolezni (skupna ocena KPSS ob vključitvi 11 do 23), v katero je bilo zajeto 470 bolnikov, so bili bolniki randomizirani.
In another monotherapy study in mild to moderate Alzheimer’s disease a total of 470 patients (MMSE total scores at baseline of 11-23) were randomised.
V drugi študiji zdravljenja z monoterapijo pri blagi do zmerni Alzheimerjevi bolezni (skupna ocena KPSS ob vključitvi 11 do 23 točk), je bilo zajetih in naključno razdeljenih 470 bolnikov.
In another multicentre, randomised, double-blind, active-controlled, parallel group study, a total of 947 patients with mild to severe hypertension who were not adequately controlled on amlodipine
V drugi multicentrični, dvojno slepi raziskavi z aktivnim primerjalnim zdravilom in paralelnimi skupinami je 947 naključnih bolnikov z neustrezno uravnano blago do hudo hipertenzijo med zdravljenjem z 10-mg odmerkom amlodipina jemalo zdravilo Onduarp (40 mg/10 mg ali
In another open-label single-arm study, 60 patients with extended oligoarthrits (15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to 17 years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) administered weekly for
V drugi odprti študiji z eno skupino se je z zdravilom Enbrel v odmerku 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden zdravilo 60 bolnikov z razširjenim oligoartritisom (15 bolnikov, starih od 2 do 4 leta, 23 bolnikov, starih od 5 do 11 let, in 22 bolnikov, starih od 12 do 17 let), 38 bolnikov z artritisom, povezanim z entezitisom (starih od 12 do 17 let) in 29 bolnikov s psoriatičnim artritisom (starih od 12 do 17 let).
In another phase 3 double-blind, placebo-controlled study in patients with SBS, who required parenteral nutrition, patients received a 0.05 mg/kg/day dose (n = 35), a 0.10 mg/kg/day dose (n = 32) of teduglutide or placebo (n = 16) for up to 24 weeks.
V drugi dvojno slepi, s placebom kontrolirani študiji 3. faze pri bolnikih s SKČ, ki so potrebovali parenteralno prehrano, so bolniki prejemali odmerek teduglutida 0,05 mg/kg/dan (n = 35), odmerek teduglutida 0,10 mg/kg/dan (n = 32) ali placebo (n = 16) do 24 tednov.
In another randomised phase III trial which compared IV topotecan to cyclophosphamide, Adriamycin (doxorubicin) and vincristine (CAV) in patients with relapsed, sensitive SCLC, the overall response rate was 24.3% for topotecan compared to 18.3% for the CAV group.
V drugem randomiziranem preskušanju III. faze, v katerem so primerjali intravenski topotekan s ciklofosfamidom, zdravilom Adriamycin (doksorubicinom) in vinkristinom (CAV), je bila pri bolnikih s ponovitvijo za zdravilo občutljivega drobnoceličnega pljučnega raka skupna stopnja odziva na topotekan 24,3 %, v primerjavi z 18,3 % v skupini, ki je prejemala kombinacijo CAV.
In another single-centre trial, 21 patients with malignant glioma received 0.2, 2, or 20 mg/kg body weight 5-ALA HCl followed by fluorescence-guided tumour resection.
V drugem enocentričnem preskušanju je 21 bolnikov z malignim gliomom prejelo 0,2, 2 ali 20 mg 5- ALA HCl/kg telesne mase, čemur je sledila resekcija tumorja, vodena s fluorescenco.
In another study cats received tablets before orthopaedic surgery (of moderate nature) and then once daily for up to two days after surgery.
V drugi študiji so mačke tablete prejele pred ortopedskim operativnim posegom (zmerne zahtevnosti) in nato enkrat dnevno do največ dva dni po njem.
In another study enrolling renal transplant patients 20 years of age and below that was intended to assess the safety of progressive corticosteroid withdrawal (beginning at six months post-transplantation) from an immunosuppressive regimen initiated at transplantation that included full-dose immunosuppression with both Rapamune and a calcineurin inhibitor in combination with basiliximab induction, of the 274 patients enrolled, 19 (6.9%) were reported to have developed post-transplant lymphoproliferative disorder (PTLD).
V drugi študiji, v katero so bili vključeni bolniki po ledvični presaditvi, stari največ 20 let, in ki je bila namenjena za oceno varnosti postopnega zmanjševanja odmerka kortikosteroidov (z začetkom šest mesecev po presaditvi) iz imunosupresivnega režima zdravljenja, začetega ob presaditvi, ki je vključeval polno imunosupresijo z zdravilom Rapamune in z zaviralcem kalcinevrina sočasno z indukcijo basiliksimaba, so pri 19 (6,9 %) od 274 vključenih bolnikov poročali o razvoju potransplantacijske limfoproliferativne bolezni (PTLD  Post-Transplant Lymphoproliferative Disorder).
In another study in 49 patients, Zutectra was given at least one week (approximately 8-11 days) after the liver transplant.
V drugi študiji, ki je vključevala 49 bolnikov, se je zdravljenje z zdravilom Zutectra začelo najmanj en teden (približno 8–11 dni) po presaditvi jeter.
In another study in men (study CZOL446M2308) an annual infusion of zoledronic acid was non- inferior to weekly alendronate for the percentage change in lumbar spine BMD at month 24 relative to baseline.
V drugi študiji z moškimi (študija CZOL446M2308) letna infuzija zoledronske kisline ni bila slabša od tedenske uporabe alendronata glede odstotka spremembe mineralne gostote kosti ledvene hrbtenice po 24 mesecih v primerjavi z izhodiščem.
In another study of 76 children whose cancer returned after earlier treatment, around 40% of Oncaspar-treated patients (some of whom were allergic to other asparaginase treatments) were cleared of the cancer, compared with 47% of patients treated with an asparaginase comparator.
V drugi študiji s 76 otroki, pri katerih se je rak po predhodnem zdravljenju ponovno pojavil, je bilo raka ozdravljenih približno 40 % bolnikov, zdravljenih z zdravilom Oncaspar (med njimi so bili nekateri alergični na druga zdravila z asparaginazo), in 47 % bolnikov, zdravljenih s primerjalnim zdravilom z asparaginazo.
In another study, amenorrhea was reported in 95% of the women who received CE
V drugi študiji so o amenoreji poročali pri 95 % žensk, ki so prejemale kombinacijo
In another study, dogs treated orally with difloxacin at 10 times the recommended dose for 10 days showed occasionally mild adverse reactions such as orange/yellowing discoloration of the faeces, emesis and hypersalivation.
Pri desetkrat večjih odmerkih, danih peroralno v obdobju 10 dni, pa so se pokazali blagi neželeni učinki, kot je rumeno-oranžno obarvano blato, emezija in povečano slinjenje
In another study, grapefruit juice had no effect on the disposition of desloratadine.
V drugi študiji so ugotavljali, da sok grenivke ne vpliva na odstranjevanje desloratadina.
In another study, rats also received the same semi-synthetic insulin via an intraperitoneally implanted osmotic mini-pump infusion for up to 6 weeks.
V drugi študiji so podgane do 6 tednov prejemale enak polsintezni insulin z intraperitonealno infuzijo po vsajeni osmotski mini-črpalki.
In another trial, the pharmacokinetics of abiraterone were examined in subjects with pre-existing severe (n = 8) hepatic impairment (Child-Pugh Class C) and in 8 healthy control subjects with normal hepatic function.
V drugem preskušanju so farmakokinetiko abiraterona raziskovali pri bolnikih z obstoječo hudo okvaro jeter (n=8) (Child-Pugh razred C) in pri 8 kontrolnih zdravih preiskovancih z normalnim delovanjem jeter.
In antiretroviral naive adult patients
Pri odraslih bolnikih, ki se predhodno še niso zdravili s protiretrovirusnimi zdravili
In antiretroviral treatment experienced patients from Studies 009, 043, and 045, 100 isolates from patients designated as virological failures on therapy that included either atazanavir, atazanavir + ritonavir, or atazanavir + saquinavir were determined to have developed resistance to atazanavir.
Pri bolnikih v študijah 009, 043 in 045, ki so se predhodno že zdravili s protiretrovirusnimi zdravili, so pojav odpornosti proti atazanavirju odkrili pri 100 izolatih bolnikov z ugotovljeno virološko odpovedjo ob terapiji, ki je vključevala atazanavir, atazanavir + ritonavir ali atazanavir + sakvinavir.
In antiretroviral treatment-naïve adults, emtricitabine was significantly superior to stavudine when both medicinal products were taken in combination with didanosine and efavirenz through 48 weeks of treatment.
Pri odraslih, ki se z protiretrovirusnim zdravilom zdravijo prvič, je bil emtricitabin opazno močnejši od stavudina, ko sta bili obe zdravili uporabljeni v kombinaciji z didanozinom in efavirenzom v času 48-tedenskega zdravljenja.
In any case, initiation of susceptible NRTI’s should always be preferred to maintenance of lamivudine therapy.
V vsakem primeru ima uvedba zdravljenja z NRTI, proti katerim virus ni odporen, prednost pred nadaljnjo uporabo lamivudina.
In any case, tenecteplase should not be re- administered before assessment of haemostatic factors like fibrinogen, plasminogen and alpha2- antiplasmin.
Tenekteplaze ne smemo ponovno dajati, ne da bi prej določili hemostatske faktorje, kot so fibrinogen, plazminogen in antiplazmin alfa2.
In any case, when bivalirudin is combined with a platelet inhibitor or an anticoagulant, clinical and biological parameters of haemostasis should be regularly monitored.
Če bivalirudin uporabljate v kombinaciji z zaviralcem krvnih ploščic ali antikoagulantom, redno nadzorujte klinične in biološke parametre hemostaze.
In approximately 12% of CAPS patients tested with a PPD (purified protein derivative) skin test in clinical trials, follow-up testing yielded a positive test result while treated with Ilaris without clinical evidence of a latent or active tuberculosis infection.
Pri približno 12 % bolnikov, ki imajo katerega od s kriopirinom povezanih periodičnih sindromov in so jim v kliničnih preskušanjih izvedli kožni test s PPD (s prečiščenim proteinskim derivatom), je pri kontrolnem testiranju v času zdravljenja z zdravilom Ilaris prišlo do pozitivnih rezultatov, ne da bi imeli bolniki klinične znake latentne ali aktivne tuberkuloze.
In approximately 13 out of 100 patients infusion reactions can occur, which may include feeling sick (nausea), fever, chills, feeling tired, headache, loss of appetite.
Pri približno 13 od 100 bolnikov se lahko pojavijo infuzijske reakcije, ki se lahko kažejo kot slabost, zvišana telesna temperatura, mrzlica, utrujenost, glavobol, izguba apetita.
In approximately half of the cases, the ERG changes had resolved at the time of the last follow-up.
V približno polovici primerov so spremembe ERG ob zadnjem kontrolnem pregledu izzvenele.
In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms.
Na področjih, ki so okužena z Dirofilario immitis, mesečno dajanja zdravila preprečuje ponovne infestacije z različnimi vrstami glist.
In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworm, hookworms and whipworms.
Na področjih, ki so okužena z Dirofilario immitis, mesečno dajanja zdravila preprečuje ponovne infestacije z različnimi vrstami glist.
In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms.
Na področjih, ki so okužena z Dirofilario immitis, mesečno dajanja zdravila preprečuje ponovne infestacije z različnimi vrstami glist.
In areas of low or no infection pressure a benefit/risk assessment must be undertaken by the veterinarian before deciding to use the vaccine in dogs.
Na območjih, kjer je okuženost nizka ali je sploh ni, mora veterinar oceniti razmerje korist/i oz. tveganja , preden se odloči za uporabo cepiva za pse pri psih.
In areas where heartworm infection does not occur, dogs may be given a single dose of Trifexis to prevent seasonal fleas when infections with gut nematodes have been
Na območjih, kjer se okužba s srčno glisto ne pojavlja, se lahko uporabi en odmerek zdravila Trifexis kot del sezonske preventive proti bolham pri psih z diagnozo okužbe prebavil
In areas where heartworm infection is known to occur, the first dose should be given one month before the expected appearance of mosquitoes and then at monthly intervals during the time of year when mosquitoes and fleas are present, until at least one month after the last exposure to mosquitoes.
Na območjih, kjer se pojavlja srčna glista, je treba prvi odmerek dati en mesec pred pričakovanim pojavom komarjev in nato v mesečnih intervalih v tistem obdobju leta, ko so prisotni komarji in bolhe, in še najmanj en mesec po zadnji izpostavljenosti komarjem.
In areas where hepatitis B is common, vaccination against hepatitis B at birth should be continued as normal, with Tritanrix HepB started at six weeks of age.
V področjih, kjer je hepatitis B pogost, je treba po cepljenju proti hepatitisu B ob rojstvu nadaljevati s cepivom Tritanrix HepB pri šestih tednih starosti.
In artificially induced inflammation in dogs, robenacoxib reduced pain and inflammation with single oral doses ranging from 0.5 to 8 mg/kg and a rapid onset of action (0.5 h).
Pri umetno induciranih vnetjih pri psih je robenakoksib pričel delovati hitro (0,5 h) in zmanjšal bolečino in vnetje z enkratnimi peroralnimi odmerki od 0,5 do 8 mg/kg.
In AS Study 2, among 72 patients initially randomised to Cosentyx 150 mg, 61 (84.7%) patients were still on treatment at Week 52.
V 2. študiji ankilozirajočega spondilitisa je med 72 bolniki, ki so bili že takoj randomizirani na prejemanje zdravila Cosentyx 150 mg, 61 bolnikov(84,7%) ob koncu 52. tedna še vedno prejemalo zdravilo.
In AS Study 2, treatment with Cosentyx 150 mg resulted in greater improvement in measures of disease activity compared with placebo at Week 16 (see Table 7).
V 2. študiji ankilozirajočega spondilitisa je zdravljenje z zdravilom Cosentyx 150 mg po 16 tednih povzročilo večje izboljšanje po merilih aktivnosti bolezni kot uporaba placeba (glejte preglednico 7).
In asfotase alfa clinical studies adverse events of craniosynostosis (associated with increased intracranial pressure), including worsening of pre-existing craniosynostosis have been reported in hypophosphatasia patients < 5 years of age.
V kliničnih študijah z asfotazo alfa so kot o neželenih učinkih poročali o kraniosinostozi (povezani z povečanim intrakranialnim tlakom), vključno s poslabšanjem obstoječe kraniosinostoze, pri bolnikih s hipofosfatazijo, starih < 5 let.
In asfotase alfa clinical studies ophthalmic (conjunctival and corneal) calcification and nephrocalcinosis have been reported in patients with hypophosphatasia.
V kliničnih študijah z azfotazo alfa so pri bolnikih s hipofosfatazijo poročali o očesnih (vezničnih in roženičnih) kalcifikacijah in nefrokalcinozi.
In assays relating to potential substance effects on mitochondrial structure and DNA content and function, lamivudine lacked appreciable toxic effects.
V testiranjih potencialnih vplivov učinkovine na mitohondrijsko strukturo, vsebnost in funkcijo DNA lamivudin ni imel znatnih toksičnih učinkov.
In association with severe neutropenia, fever or infection occurred in 16 % of patients during course 1 and overall in 23 % of patients (6 % of courses).
Ob hudi nevtropeniji so med prvim ciklom zdravljenja pri 16 % bolnikov opazili zvišano telesno temperaturo ali različne okužbe, 23 % bolnikov pa je imelo takšne neželene učinke ves čas (6 % ciklov zdravljenja).
In association with severe neutropenia, fever or infection occurred in 16 % of patients during course 1 and overall in 23 % of patients (6 % of courses).
Ob hudi nevtropeniji so med prvim ciklom zdravljenja pri 16 % bolnikov opazili zvišano telesno temperaturo ali različne okužbe, med celotnim obdobjem zdravljenja pa je imelo takšne neželene učinke 23 % bolnikov (6 % ciklov zdravljenja).
In association with severe neutropenia, fever or infection occurred in 16% of patients during course 1 and overall in 23 % of patients (6 % of courses).
Ob hudi nevtropeniji so med prvim ciklom zdravljenja pri 16 % bolnikov opazili zvišano telesno temperaturo ali različne okužbe, 23 % bolnikov pa je imelo takšne neželene učinke ves čas (6 % ciklov zdravljenja).
In asthma, Aerivio Spiromax can be used in patients whose disease is not adequately controlled despite treatment with a combination of a beta-2 agonist and a lower dose of inhaled corticosteroid, or those whose asthma is already controlled with a long-acting beta-2 agonist and a high-dose of inhaled corticosteroid.
Pri astmi se lahko zdravilo Aerivio Spiromax uporablja pri bolnikih, pri katerih bolezen ni pod ustreznim nadzorom kljub zdravljenju s kombinacijo agonista adrenergičnih receptorjev beta-2 in manjšega odmerka inhalacijskega kortikosteroida, in pri bolnikih, pri katerih je astma nadzorovana že z dolgodelujočim agonistom adrenergičnih receptorjev beta-2 in velikim odmerkom inhalacijskega kortikosteroida.
In asthma, Airexar Spiromax can be used in patients whose disease is not adequately controlled despite treatment with a combination of a beta-2 agonist and a lower dose of inhaled corticosteroid, or those whose asthma is already controlled with a long-acting beta-2 agonist and a high-dose of inhaled corticosteroid.
Pri astmi se lahko zdravilo Airexar Spiromax uporablja pri bolnikih, pri katerih bolezen ni pod ustreznim nadzorom kljub zdravljenju s kombinacijo agonista adrenergičnih receptorjev beta-2 in manjšega odmerka inhalacijskega kortikosteroida, in pri bolnikih, pri katerih je astma nadzorovana že z dolgodelujočim agonistom adrenergičnih receptorjev beta-2 in velikim odmerkom inhalacijskega kortikosteroida.
In at-risk patients treated with Simponi, an invasive fungal infection should be suspected if they develop a serious systemic illness.
Pri bolnikih s tveganjem, ki so zdravljeni z zdravilom Simponi, je treba v primeru pojava resne sistemske bolezni posumiti na invazivno glivno okužbo.
In atopic dermatitis, an over-reaction of the skin’s immune system causes skin inflammation (itchiness, redness and dryness).
Pri atopičnem dermatitisu čezmerna reakcija imunskega sistema kože povzroči njeno vnetje (srbenje, pordelost in izsušenost).
In atopic dermatitis, an over-reaction of the skin’s immune system causes skin inflammation (itchiness, redness, dryness).
Pri atopičnem dermatitisu čezmerna reakcija imunskega sistema v koži povzroči vnetje kože (srbenje, pordelost, suhost).
In Atypical Haemolytic Uremic Syndrome (aHUS):
Pri atipičnem hemolitično uremičnem sindromu (aHUS):
In B-ALL patients with relapse 18 36 months from diagnosis (n = 33) the CR rate was 79% (95% CI: 61, 91) and the 4-month event free survival rate was 73% (95% CI: 54, 85).
Pri bolnikih z B-celično ALL in relapsom po 18–36 mesecev po diagnozi (n = 33) je bil delež popolnih odgovorov 79 % (95% CI: 61, 91) in delež 4-mesečnega preživetja bolnikov brez dogodkov 73 % (95% CI: 54, 85).